Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026568 · ClinicalTrials.gov registry record · Phase 2
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04026568 is a Phase 2 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT04026568, a Phase 2 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
Interventions
- DRUG 4-Aminopyridine
- DRUG Placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2022-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026568
The ClinicalTrials.gov registry entry for NCT04026568 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 4-Aminopyridine is the first listed.
NCT04026568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026568 about?
NCT04026568 is a clinical study titled "A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma". The purpose of this study is to evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after per...
What is the current status of trial NCT04026568?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-08-17. Estimated completion is 2022-07-18.
What interventions are being tested in trial NCT04026568?
The interventions under investigation include: 4-Aminopyridine (DRUG), Placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04026568?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.